- Home
- KEP vs EXEL Comparison
KEP vs EXEL Comparison
Compare KEP & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KEP | EXEL |
|---|---|---|
| Founded | 1961 | 1994 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5B | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | KEP | EXEL |
|---|---|---|
| Price | $16.49 | $43.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 23 |
| Target Price | N/A | ★ $45.18 |
| AVG Volume (30 Days) | 384.3K | ★ 2.6M |
| Earning Date | 02-27-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 122.08 | 53.55 |
| EPS | ★ 9.13 | 2.38 |
| Revenue | ★ $69,245,145,923.00 | $2,288,218,000.00 |
| Revenue This Year | $5.36 | $9.79 |
| Revenue Next Year | $2.32 | $12.01 |
| P/E Ratio | ★ $3.59 | $18.53 |
| Revenue Growth | 5.27 | ★ 9.93 |
| 52 Week Low | $6.68 | $31.90 |
| 52 Week High | $18.29 | $49.62 |
Technical Indicators
Market Signals| Indicator | KEP | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.81 | 52.40 |
| Support Level | $16.35 | $40.83 |
| Resistance Level | $17.10 | $47.24 |
| Average True Range (ATR) | 0.24 | 1.11 |
| MACD | -0.09 | 0.04 |
| Stochastic Oscillator | 14.74 | 48.94 |
Price Performance
Historical ComparisonAbout KEP Korea Electric Power Corporation
Korea Electric Power Corp is an electric utility company in which the government of South Korea holds a controlling stake. The firm operates in the following segments: Transmission and distribution, Electric power generation (Nuclear), Electric power generation (Non-Nuclear), Plant maintenance & engineering service, and Others. The majority of the energy produced by the company comes from its nuclear and coal-fired assets. Korea Electric Power generates revenue through the Transmission and distribution segment. Geographically, it derives maximum revenue from Domestic operations.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.